Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Evaluation of medical provider practice patterns in the assessment and management in heavy menstrual bleeding for patients on anticoagulation

Michael Pfeffer, Bethany Samuelson Bannow, Amanda French et al. Nov 03, 2025 pp. 4464-4464 10.1182/blood-2025-4464

Abstract Introduction: Heavy menstrual bleeding (HMB), traditionally defined as menstrual blood loss of greater than 80 mL per menstrual cyc...

Evaluating leukemogenic transmission via blood transfusion from genetically modified leukemic mice to healthy recipients

Mohammad Amin Elahi Najafi, Amanda Streeter, Bianca Santonastaso et al. Nov 03, 2025 pp. 1369-1369 10.1182/blood-2025-1369

Abstract Background: Donor-derived leukemia after stem-cell transplantation is documented, yet the risk of transmitting leukemogenic cells v...

Targeting CD117 with engineered invariant natural killer T cells (iNKT Cells) as a novel approach for acute myeloid leukemia treatment

Chaiyaporn Boonchalermvichian, Hao Yan, Jeanette Baker et al. Nov 03, 2025 pp. 7662-7662 10.1182/blood-2025-7662

Abstract Background: Our research focuses on developing a CAR-based therapy for acute myeloid leukemia (AML) using engineered invariant natu...

Enhancing specificity in factor v leiden screening: Performance of the hemoclot quanti v-l assay

Joshua Wischmeyer, Christine Baird, Dianne Thornhill et al. Nov 03, 2025 pp. 1341-1341 10.1182/blood-2025-1341

Abstract Introduction: Factor V Leiden (FVL) is an autosomal dominant prothrombotic disorder, that impacts activated Fac...

Craniofacial involvement is associated with poor prognosis in extranodal DLBCL patients

Jian-guo Fang, Jia-min Hua, Wei Lu et al. Nov 03, 2025 pp. 3658-3658 10.1182/blood-2025-3658

Abstract Background: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous and aggressive lymphoma, with approximately one-third of cases...

Effect of avapritinib on skin lesions in patients with advanced systemic mastocytosis using a novel, artificial intelligence-based technology

Deepti Radia, Tracy George, Iván Álvarez-Twose et al. Nov 03, 2025 pp. 2030-2030 10.1182/blood-2025-2030

Abstract IntroductionAdvanced systemic mastocytosis (AdvSM), which includes aggressive SM (ASM), SM with an associated hematologic neoplasm...

Differential impact of clonal hematopoietic mutations on 10-year atherosclerotic cardiovascular disease risk from a multidisciplinary chip clinic

Shyam Patel, Rena Zheng, Victor Acosta-Rivera et al. Nov 03, 2025 pp. 6705-6705 10.1182/blood-2025-6705

Abstract Background: Clonal hematopoiesis (CH) is characterized by the expansion of the hematopoietic stem/progenitor pool in the setting of...

Correlation between CRLF2 expression by flow cytometry and FISH in patients diagnosed with B-cell acute lymphoblastic leukemia

Flavia Sousa, Elizabeth Souto, Laiz Bento et al. Nov 03, 2025 pp. 6832-6832 10.1182/blood-2025-6832

Abstract Introduction / Objective: Philadelphia chromosome–like B-cell acute lymphoblastic leukemia (Ph-like B-ALL), also referred to as BCR...

Role of bortezomib maintenance therapy in the anti-CD38 antibody era: Interim analysis results of a randomized Phase III study for transplant-ineligible newly diagnosed multiple myeloma (JCOG1911/B-DASH Study)

Tomotaka Suzuki, Ryunosuke Machida, Yusuke Sano et al. Nov 03, 2025 pp. 370-370 10.1182/blood-2025-370

Abstract Introduction Daratumumab (Dara) plus melphalan, prednisolone, and bortezomib (Bor) (D-MPB), followed by Dara maintenance therapy, h...

Trimodal single-cell profiling reveals principles of cell fate acquisition in human erythropoiesis.

Steven Tur, Carmen Palii, Sirui Yan et al. Nov 03, 2025 pp. 967-967 10.1182/blood-2025-967

Abstract Hematopoiesis is a highly dynamic and hierarchical process that gives rise to all blood cell types from multipotent hematopoietic s...

In Vivo hematopoietic stem cell (HSC) engineering and selection with CD90-targeted multiplexed virus-like particles (MVPs) for HSC gene therapy and cancer immunotherapy

Stefan Radtke, Justin Thomas, Seunga Choo et al. Nov 03, 2025 pp. 1065-1065 10.1182/blood-2025-1065

Abstract Ex vivo hematopoietic stem cell (HSC) gene therapy can cure various blood and immune disorders. However, barriers persist regarding...

Quantitative real-time polymerase chain reaction coupled with high-resolution melting (HRM) for simultaneous detection and quantification of four isoforms of BCR::ABL1

Ting Zhou, Ayman Mohamed, Ben Legendre et al. Nov 03, 2025 pp. 6135-6135 10.1182/blood-2025-6135

Abstract Background The diagnosis and management of chronic myeloid leukemia (CML) critically rely on detecting and serially quantifying BCR...

Rivaroxaban in pediatric venous malformations complicated by thrombosis: Updated experience from a retrospective single-center cohort

Ariela Smigliani, Angelo Molinari, Giovina Di Felice et al. Nov 03, 2025 pp. 4911-4911 10.1182/blood-2025-4911

Abstract Background and Aims Venous malformations (VMs) are the most prevalent subtype of congenital vascular malformations and may be compl...

Luspatercept in β-thalassemia: Meta-analysis of efficacy and safety across transfusion-dependent and non-transfusion-dependent populations

Yashaswi Guntupalli, Venkata Kanishk Yannakula, Amruth Alluri et al. Nov 03, 2025 pp. 1145-1145 10.1182/blood-2025-1145

Abstract Background: Luspatercept is a first-in-class erythroid maturation agent approved for adult transfusion-dependent β-thalassemia. Pha...

Spatial transcriptomics identified dynamic and spatial-resolved niche cell and signal architecture for hematopoietic stem cell specification

Xinjian Mao, Ning Zhang, Xi He et al. Nov 03, 2025 pp. 3151-3151 10.1182/blood-2025-3151

Abstract Hematopoietic stem cell (HSC) transplantation remains limited by insufficient matched donors. Generating HSCs from pluripotent stem...

Maximizing the potential of optical genome mapping through comprehensive automated data analysis in multiple myeloma

David Martínez-Campuzano, Alicia Gómez, Neus Torres et al. Nov 03, 2025 pp. 7449-7449 10.1182/blood-2025-7449

Abstract Introduction: Identifying cytogenetics abnormalities (CAs) is essential to define prognosis in patients with newly diagnosed multip...

Phase 3 study (inMIND) of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes of high-risk patients

Kai Huebel, Paolo Strati, Laurie Sehn et al. Nov 03, 2025 pp. 5367-5367 10.1182/blood-2025-5367

Abstract Introduction: Despite initial response to first-line therapy, most patients (pts) with follicular lymphoma (FL) experience relapse...

MYC-dependent permissiveness of PI3K hyperactivation renders metabolic vulnerability in R/R b-ALL

Junzhe Song, Huimin Liu, Xiaotian Ji et al. Nov 03, 2025 pp. 1475-1475 10.1182/blood-2025-1475

Abstract Significance Phosphoinositide-3 kinase (PI3K) and MYC are recognized as central components of a shared signaling network that regul...

Distinct sialylation profiles of neonatal and adult platelets revealed by lectin flow cytometry

Muataz Ali Hamad, Kelsey Rodrigues, James Lee et al. Nov 03, 2025 pp. 1238-1238 10.1182/blood-2025-1238

Abstract Neonatal platelets differ from adult platelets in their activation thresholds, in vivo half-life, and hemostatic function. We and o...

Luspatercept combined with immunosuppressive therapy reduces inflammation in aplastic anemia by inhibiting monocyte pyroptosis

Zining Wang, Nan Song, Chunyan Liu et al. Nov 03, 2025 pp. 4976-4976 10.1182/blood-2025-4976

Abstract Abstract Background: Aplastic anemia (AA) is a bone marrow failure disorder caused by diverse etiologies. AA pathogenesis involves...

Clinical outcomes of patients with IDH1/IDH2-mutated clonal hematopoiesis: A single-center retrospective study

Fnu Amritpal Singh, Koji Sasaki, Sanam Loghavi et al. Nov 03, 2025 pp. 6710-6710 10.1182/blood-2025-6710

Abstract Introduction:  Clonal hematopoiesis is defined by the expansion of hematopoietic stem or progenitor cells carry...

FOXO1⁺themis⁺ memory t cells underpin long-term remission after cytokine-armored CD19 CAR-t therapy in refractory lymphoma

Wenbin Qian, Aiqi Zhao, Hui Liu et al. Nov 03, 2025 pp. 3707-3707 10.1182/blood-2025-3707

Abstract In an extended 5-year follow-up of a single-arm, multicenter trial (NCT04833504) evaluating IL-7/CCL19-armored CD19 CAR-T (7×19 CAR...

Sickling kinetics drive genotype-specific impairment of RBC deformability in sickle cell disease

Yuxuan Du, Zoe Sekyonda, Umut Gurkan Nov 03, 2025 pp. 4712-4712 10.1182/blood-2025-4712

Abstract Introduction: Sickle cell disease (SCD) is an inherited hemoglobinopathy arising from a single point mutation in the β-globin gene...

Prospective observational cohort study to collect granular social determinants of health data for hematopoietic cell transplant patients

Warren Fingrut, KaNoisha Codrington, Denai Milton et al. Nov 03, 2025 pp. 6163-6163 10.1182/blood-2025-6163

Abstract Background: Although patient (pt) social/financial barriers impact transplant (BMT) outcomes, comprehensive, granular social determ...

Prehabilitation prior to CAR T-cell therapy in non-Hodgkin lymphoma: Baseline physical function and toxicity outcomes

Rahul Shah, Zhiping Luo, Rhodora Fontillas et al. Nov 03, 2025 pp. 2719-2719 10.1182/blood-2025-2719

Abstract Background Emerging evidence suggests that baseline physical function may predict the toxicity of chimeric antigen receptor (CAR) T...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page